Patents by Inventor Andrew J. Souers

Andrew J. Souers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Macrocyclic MCL-1 inhibitors and methods of use
    Publication number: 20190055264
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: August 15, 2018
    Publication date: February 21, 2019
    Inventors: Patrick B. Brady, Wilfried Braje, Yujia Dai, George A. Doherty, Jane Gong, Katja Jantos, Cheng Ji, Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Anthony Mastracchio, Roberto M. Risi, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Xilu Wang, Michael D. Wendt, Yiyun Yu, Guidong Zhu, Thomas D. Penning
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20180251426
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: October 13, 2017
    Publication date: September 6, 2018
    Inventors: Milan Bruncko, Yujia Dai, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura Hexamer, Aaron R. Kunzer, Robert A. Mantei, Chang H. Park, Cheol-Min Park, Andrew M. Petros, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, William J. McClellan
  • ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20170355769
    Abstract: The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: December 14, 2017
    Inventors: Lorenzo Benatuil, Milan Bruncko, Debra Chao, Kamel Izeradjene, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers, Archana Thakur
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20170296531
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: December 7, 2015
    Publication date: October 19, 2017
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew J. Souers
  • Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors
    Publication number: 20170182179
    Abstract: Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
    Type: Application
    Filed: December 9, 2015
    Publication date: June 29, 2017
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Erwin R. Boghaert, Milan Bruncko, George Doherty, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch
  • APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20170158666
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: July 25, 2016
    Publication date: June 8, 2017
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
  • Pyridine CDK9 kinase inhibitors
    Patent number: 9650358
    Abstract: Disclosed are compound of Formula (Ia), wherein R2, R12, R16, J, Q, X, Y and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (Ia).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 16, 2017
    Assignee: AbbVie Inc.
    Inventors: Anthony Mastracchio, Milan Bruncko, Chunqiu Lai, Julie M. Miyashiro, Zhi-Fu Tao, Keith W. Woods, Thomas D. Penning, Andrew J. Souers
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20170096424
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: June 30, 2016
    Publication date: April 6, 2017
    Inventors: Zhi-Fu Tao, Xilu Wang, Andrew J. Souers, Nathaniel D. Catron, Gerard M. Sullivan
  • BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same
    Publication number: 20160339117
    Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
    Type: Application
    Filed: December 9, 2015
    Publication date: November 24, 2016
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20160304451
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: February 19, 2016
    Publication date: October 20, 2016
    Inventors: Steven W. Elmore, Aaron R. Kunzer, Robert A. Mantei, Andrew J. Souers, Gerard M. Sullivan, Gary T. Wang, Le Wang, Michael D. Wendt
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 9403822
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: August 2, 2016
    Assignee: ABBVIE INC.
    Inventors: Zhi-Fu Tao, Xilu Wang, Andrew J Souers, Nathaniel D. Catron, Gerard M. Sullivan
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20160158218
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: December 7, 2015
    Publication date: June 9, 2016
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew J. Souers
  • BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same
    Publication number: 20160158377
    Abstract: Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
    Type: Application
    Filed: December 9, 2015
    Publication date: June 9, 2016
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • 7-substituted indole Mcl-1 inhibitors
    Patent number: 9359296
    Abstract: Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: June 7, 2016
    Assignee: ABBVIE INC.
    Inventors: Xilu Wang, Xiaohong Song, Steven W. Elmore, Milan Bruncko, David J. Madar, Andrew J. Souers, Lisa A. Hasvold, Le Wang, Zhi-Fu Tao, Aaron R. Kunzer
  • Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors
    Patent number: 9346813
    Abstract: Disclosed are compound of Formula (Ia), wherein R1, R2, and R3 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 24, 2016
    Assignee: AbbVie Inc.
    Inventors: Alan S. Florjancic, Yunsong Tong, Thomas D. Penning, Andrew J. Souers, Rajeev Goswami, Zhi-Fu Tao
  • Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
    Patent number: 9315488
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: April 19, 2016
    Assignee: ABBVIE INC.
    Inventors: Hong Ding, Steven W. Elmore, Lisa Hasvold, Laura A. Hexamer, Aaron R. Kunzer, William J. McClellan, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Michael D. Wendt
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 9303025
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: April 5, 2016
    Assignee: AbbVie Inc.
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura Hexamer, Aaron R. Kunzer, Robert A. Mantei, Cheol-Min Park, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt
  • BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES
    Publication number: 20160009687
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: May 29, 2015
    Publication date: January 14, 2016
    Inventors: Hong Ding, Steven W. Elmore, Lisa Hasvold, Laura A. Hexamer, Aaron R. Kunzer, William J. McClellan, Gerard M. Sullivan, Andrew J. Souers, Zhi-Fu Tao, Michael D. Wendt
  • APOPTOSIS-INDUCING AGENT FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20160002187
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: September 15, 2015
    Publication date: January 7, 2016
    Inventors: Aaron R. Kunzer, Steven W. Elmore, Laura A. Hexamer, Cheol-Min Park, Andrew J. Souers, Gerard M. Sullivan, Gary T. Wang, Xilu Wang, Michael D. Wendt
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 9227963
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: January 5, 2016
    Assignee: ABBVIE INC.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew J. Souers